Jake Fishman’s Post

Venture capital funding of medical imaging AI developers continues to slow. A new report from Signify Research Ltd shows that funding declined 19% in 2023, and is off to a slow start in 2024 as well. Read more at https://buff.ly/3wteHoz #radiology #ImagingAI

Another great report summarizing #VCFunding for #ClinicalAI companies and the growing medical imaging AI landscape. 💡 2023 Funding Raised: $626.7M Number of Deals: 33 Average Deal Size: $19M Clinical AI is an established and growing market. 🔎 Since 2015 Funding Raised: $5.3B Companies Funded: 198 Deals Completed: 563 Median Funding per Company: $6.8M Median Deal Size: $2.1M Key Take Aways from Ellie Baker at Signify Research Ltd ➡ Vendors required to demonstrate revenue potential and provide a clear path to ROI. ➡ Signify Research expecting some deal volume to be low as many vendors reporting 2024 & 2025 the year they breakeven. ➡ 2024 Funding Rounds generated have been Seed/Series A investments Signify Research provide deep market intelligence around AI in Medical Imaging. https://lnkd.in/gVjn7p2C

deepc closes another round of funding to accelerate its growth and solidify its role in AI deployment in the clinic !👇 Reflecting on early conversations with Dr. Franz MJ Pfister, MD, MBA, I am amazed by how his vision and yesterday's ideas have transformed into a leading radiology AI company with customers in over 30 countries ! Platforms like deepcOS offer a turnkey solution for hospitals and clinicians, easing administrative and technical burdens of AI integration. Best of luck with the next milestones, Franz and team ! 🚀 Read more on Marty Stempniak article ; link in the comment 👇 #radiology #AI #startup #funding Sofinnova Partners Bertelsmann Investments Digital Partners

We're excited to introduce our newest Shott Scale Up Accelerator cohort. This cohort comprises fifteen driven leaders from engineering scaleups, each set to receive a year of valuable business leadership guidance and a £10,000 training grant to accelerate their professional growth. This group is a line-up of some of the UK's most promising SMEs, all with ground-breaking innovations. Get to know them below. 🔹 Iain Hendrick - CPO of Neurovalens Ltd - leading globally in non-invasive neurostimulation, to address significant health challenges by developing innovative treatments which are drug free and safe. 🔹 Peter Italiano - Managing Director, Product of H2GO Power Ltd - driving decarbonisation by intelligently enabling the deployment of clean hydrogen. 🔹 Dr Paul Reynolds - CEO of CALMFLOOR by FSD Active Ltd - reducing vibrations and carbon footprint of building floors using their patented CALMFLOOR active damping technology. 🔹 Michael Ebner - CEO and Co-founder of Hypervision Surgical Ltd - guiding the future of surgery using AI-powered hyperspectral imaging. 🔹 Dr Maxwell Munford - CEO and Founder of OSSTEC - providing knee implants with innovative lattice technology closely matching native bone properties for optimised implant fixation. 🔹 Dr Neil Gordon - VP Technology of Synaptec Ltd - performing discrete and passive measurement of electrical and mechanical parameters over wide areas on electrical power networks. 🔹 Dr Kärt Tomberg - Co-founder and CEO at ExpressionEdits Ltd - revolutionising the production of recombinant therapeutic proteins with their proprietary intronisation method and AI-powered ExEd Engine. 🔹 Dr Tara O'Driscoll, PhD - CTO and Co-founder of BoobyBiome - harnessing the untapped potential of breast milk's impact on infant health. 🔹 Keno Mario-Ghae - Head of Special Projects at The Little Car Company - producing high-quality, electric scale models of classic cars. 🔹 Katia Mandaltsi, PhD - Head of Strategy and Clinical Partnerships at Oxford Heartbeat - AI-powered software helping doctors best prepare for these high-risk procedures. 🔹 Mike Coto - Chief Commercial Officer at Plastometrex - pioneering advanced mechanical testing technologies for metallic materials. 🔹 Umaima Malik Ahmad - CEO and co-founder at 52North - creators of Neutrocheck® - providing safer care and peace of mind for people living with cancer. Affordable, cutting-edge technology to bring healthcare closer to patients. 🔹 Benjamin Redford - Chief Product Officer at Mayku - enabling localised manufacturing by making mass production techniques available on the bench-top. 🔹 Dr Theodora Ephson, Commercial Director at Ufonia - combining AI and clinical evidence to automate routine telephone consultations. 🔹 Ashima Gupta - CEO at Renew Risk Limited - providing risk modelling and analytics solutions for renewable energy assets like offshore wind farms. Daniel Boggon Cristina Lisii Maria Bataller #ShottScaleUp #startup

Exciting news today for @ Openwater as we announce we’ve reached $100M in total funding to commercialize our technology platform and advance our mission of making advanced medical care accessible worldwide. Plus: order reservations open for fully open-source breakthrough therapeutic ultrasound and biophotonics platform. More info at http://openwater.health Openwater's healthcare platform combines high-resolution infrared imaging, precision-tuned ultrasound, and targeted electromagnetic fields. This integration enables unprecedented visualization, monitoring, and treatment of biological issues. The technology can selectively destroy cancer cells while leaving healthy cells unaffected, similar to how an opera singer's voice can shatter a specific wine glass without disturbing others. Preclinical and clinical studies have shown promising results, including shrinking glioblastoma tumors in mice and treating severe depression in humans. Think of it as bringing the precision of semiconductors, software and AI with the ubiquity of consumer electronics to healthcare. New and existing investors include Plum Alley Ventures Company, Khosla Ventures, BOLD Capital Partners, Esther Dyson, Howard Morgan

𝐍𝐮𝐜𝐥𝐞𝐚𝐢 𝐭𝐡𝐞 𝐒𝐩𝐚𝐭𝐢𝐚𝐥 𝐀𝐈 𝐁𝐢𝐨𝐦𝐚𝐫𝐤𝐞𝐫 𝐒𝐭𝐚𝐫𝐭𝐮𝐩 𝐒𝐞𝐜𝐮𝐫𝐞𝐬 $𝟏𝟒 𝐌𝐢𝐥𝐥𝐢𝐨𝐧 𝐢𝐧 𝐅𝐮𝐧𝐝𝐢𝐧𝐠 Nucleai, a spatial AI biomarker company that deciphers cellular communications and maps cellular interactions within tissue samples to forecast therapeutic outcomes, disclosed on Wednesday that it has secured a $14 million investment. Read More: https://bityl.co/PAFe #nucleai #aibiomarker #AI #artificialintelligence #biomarkers #startup #startupnews #startupfunding #BusinessNews #NewsUpdate #newsdaily #thecioworld

I think this is the most unethical practice I have ever encountered. It is so unethical I was shocked when I found this out years ago.Pure horror that should definitly not be allowed as it is completely illegal if you are honest about the whole situation. I went to the man who does this in the netherlands. Thinking I was entering the future as I know it. I walked in in ectasy and came out of the meeting completely horrified. Money had taken over the stemcell research and researchers. Basically they have a foetus without skin chopped up in parts and they put that in a big machine and let flow medicine through them constantly..Big farma is the one that has the financial capacity to fund these people, who have got great results with stemcells..I belief this method is creating more illness .Tesla has proved that already.They found a way to test on humans and a hole in the system of the law.. These are real parts of humans and we are connected to that. Our stemcells do feel what is going on . Being connected to the milions of medicines that where lying there to be tested. Our stemcells will be affected by what those stemcells are going through. When you think of a metal bridge that is suddenly collapsing because of metal fatique that is happening to us humans right now. Those human parts have feelings as well and contain every part of information that will create us and our future. Just because it has no skin it does not mean it is not a foetus. It is the biggest threat on humanity I belief. Tesla has proved we can feel what is going on especially when we have the same resonance as it is our own species. In my opinion this should be stopped right now as we speak. It will cause illness beyond repair. We are talking about our human stemcells here. The knowledge we have found now is life saving. Using this knowledge in this manner, it is life taking without doubt.It is reprogramming our stemcells . Also I belief that our stemcells are capable of creating different functions in a different world. These capabilities ly dormant waiting for transformation.Like this they will stay dormant as the are tortured beyond reason.. Not being allowed to clone should also not being allowed to clone parts of humans and especially not being allowed to do tests on parts of a foetus/human. Just because it does not look human does not say it has not got all the human abbilities and all the human potential. Like this they cross every law possible that is protecting human rights and human health. Nobody is protesting about this..why not? Again this is a bio war on a level we cannot comprehend and the damage will be incredible. Medicine is not the future. Vibration, frequenties and sound are the future. Connecting with plant medicine is connecting with nature mother earth and keeps us on this planet. We got to stop this malpractice. This is not wanting to bring health, this is Dis- Ease at large and will break our immune system at the core base. Who can help me stop this? PS.

*The Rise of popaEyaam: A Revolutionary Wellness Concept* Congratulations to Dr. V K Sharma (Founder), Ms Nikita Sharma (Co-Founder) and the team popaEyaam on receiving the prestigious International Healthcare Award 2024 for their groundbreaking approach to wellness. popaEyaam's holistic concept, centered around Interactive Breathing Protocol based on Musculoskeletal Biomechanics (IBPMsB), addresses physical and mental performance needs, supporting the body's load and recovery requirements across all life stages. This innovative approach promotes growth, development, overall health, and longevity, making it a significant contributor to the wellness industry. By collaborating with institutions and leveraging cutting-edge technology, popaEyaam aims to reach a broader audience, making its unique benefits accessible to all. The "Fit-N-Fine" and "Live-99" slogans inspire individuals to prioritize their health and wellness. popaEyaam team's continued success in their endeavors, poised to make a profound impact on human lives through their remarkable wellness concept. 👇 पोपाईयाम् 👇 🫁INTERACTIVE BREATHING PROTOCOL BASED ON THE MUSCULOSKELETAL BIOMECHANICS🫀 #nutrieints #mitochondrialhealth #wellness #MobilityMatters #LongevityGuaranteed #fitnesslifestyle #lifestyle #resistancetraining #ownbodyweightstrength

Vitestro has raised $22 million funding to accelerate commercialization of its innovative robotic blood drawing device. This brings its total funding raised to $50 million from both equity investments and grant funding. The round was co-led by return investor Sonder Capital and new investor NYBC Ventures, with participation from Invest-NL, the European Innovation Council Fund (EIC Fund), and existing private investors. Toon Overbeeke, Vitestro CEO and co-founder: “Early feedback from hospitals, staff and patients has been overwhelmingly positive, and we are eager to quickly expand our reach and impact globally.” Through a combination of artificial intelligence (AI), advanced imaging technology, and robotics, Vitestro enables hospitals and labs to provide accurate and autonomous blood draws, reducing the need for manual handling and improving patient and clinician satisfaction. "Vitestro’s revolutionary device is perfectly positioned to improve patient care and streamline operations for a medical laboratory market in crisis,” said Dr. Frederic Moll, managing partner at Sonder Capital and the co-founder of Intuitive Surgical (NASDAQ:ISRG), the company behind the da Vinci surgical system. “As turnover and departures accelerate, staff are overwhelmed and labs are challenged to deliver timely test results and satisfactory care. We are excited by Vitestro’s progress and believe they will modernize the blood draw experience.” Multiple Vitestro devices have already been pre-ordered and are scheduled to be deployed at several European hospitals starting at the end of this year to help ease workload and provide a more consistent, improved patient experience. Vitestro is also currently leading the A.D.O.P.T. trial, the world’s largest evaluation of autonomous blood drawing devices. Vitestro is on track to obtain CE approval for its device by the end of 2024, with deployment efforts expected to begin in that same timeframe. INGEN HOUSZ (Quirijn van Veen, Daan Gieben) advised Vitestro.